Viking Therapeutics Financial Results Upcoming Announcement
Viking Therapeutics, Inc. focuses on discovering innovative therapies for metabolic and endocrine disorders. The company is gearing up to announce its financial results for the third quarter of 2024, after the market closes. This will be an important moment for Viking as they share insights into their growth and ongoing research.
Conference Call Details
To discuss the financial results and provide updates about corporate developments, Viking Therapeutics has scheduled a conference call. This call is set for 4:30 p.m. Eastern Time on the same day the results are released. Participating in the call is easy; stakeholders can join by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. Additionally, a playback of the call will be available until a week later for those who want to catch up.
About Viking Therapeutics
Viking Therapeutics stands at the forefront of clinical-stage biopharmaceutical innovation. With a keen focus on groundbreaking treatments, they are developing first-in-class and best-in-class therapies aimed at improving patients' lives with metabolic disorders. Their commitment to research and development is reflected in their pipeline, which includes three promising compounds in clinical trials.
Innovative Therapeutics in Development
Viking's unique approach includes the exploration of VK2735, a dual agonist targeting GLP-1 and GIP receptors, which has shown promise in treating various metabolic conditions. Phase 1 and Phase 2 trials have demonstrated its safety and potential clinical benefits. The company is also actively assessing an oral version of VK2735 in a Phase 1 trial, which could simplify treatment for patients.
Expanding the Treatment Landscape
In addition, they are advancing VK2809, a selective thyroid hormone receptor beta agonist. This compound aims to address lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Data from their recent clinical studies show that VK2809 significantly reduced LDL cholesterol and liver fat content, indicating its potential as a robust treatment option.
Future Directions for Viking
The company is set to prioritize innovative research efforts, including developing dual amylin and calcitonin receptor agonists. These are being explored for their potential in obesity treatment, showcasing Viking's commitment to tackling challenging health issues. Moreover, they are investigating VK0214 for X-linked adrenoleukodystrophy, showcasing their dedication to addressing rare diseases with significant unmet needs.
Staying Updated with Viking Therapeutics
For those eager to learn more about Viking Therapeutics and their cutting-edge work in biopharmaceuticals, their website is a great resource. Visitors can find a wealth of information on their clinical trials, product pipelines, and updates that reflect the company's growth and dedication to research excellence.
Frequently Asked Questions
When will Viking Therapeutics release their financial results?
Viking Therapeutics plans to release their financial results for the third quarter of 2024 after the market closes on October 23, 2024.
What is the purpose of the upcoming conference call?
The conference call will discuss financial results and provide updates on general corporate matters.
How can I participate in the conference call?
Participants can dial (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. to join the call.
What are VK2735 and VK2809?
VK2735 is a dual agonist for metabolic disorders, while VK2809 is a selective thyroid hormone receptor beta agonist intended for lipid and metabolic conditions.
How can I stay updated on Viking Therapeutics' news?
Interested individuals can visit Viking Therapeutics' website for the latest information on their clinical trials and product development.
